FDA Clocks Patent Extension Time for OJEMDA Drug
Published Date: 12/29/2025
Notice
Summary
The FDA has set the official review period for the drug OJEMDA, which helps the company extend its patent and protect their invention longer. This affects the drug maker and anyone tracking patent dates, with deadlines to challenge or comment on these dates by early 2026. It’s a key step to keep innovation alive while making sure the patent system stays fair and on schedule.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 0 costs, 2 mixed.
FDA sets OJEMDA review period length
FDA determined the regulatory review period for OJEMDA (tovorafenib) is 4,942 days total: 4,705 days in the testing phase and 237 days in the approval phase. FDA lists the key dates used: IND effective October 14, 2010; NDA initially submitted August 31, 2023 (NDA 217700); and approval on April 23, 2024.
Applicants seek 5-year patent extension
The applicants (Day One Biopharmaceuticals, Inc. and Viracta Therapeutics, Inc.) seek 5 years of patent-term extension for U.S. Patent No. 8,293,752. FDA notes this determination establishes the maximum potential length, but the USPTO will apply statutory limitations when calculating the actual extension.
Deadlines to challenge or petition dates
Anyone who believes the published dates are wrong may submit comments and request a redetermination by February 27, 2026. Any interested person may petition FDA about whether the applicants acted with due diligence during the regulatory review period by June 29, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11966 — Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help businesses fill out Forms FDA 3542a and FDA 3542 without confusion. If you submit these forms, this guide answers your top questions and makes the process smoother. You’ve got until August 14, 2026, to send in your feedback before the FDA finalizes the guide—no extra costs, just clearer steps!
2026-11998 — Amendment and Revocation of Organizational Information Regulations
The FDA is updating its rules to point everyone to its website for the latest contact and organizational info, ditching old, unnecessary regulations. This makes it easier for the public to find accurate info all in one place, starting June 15, 2026. If you interact with the FDA, expect smoother access with no extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
Previous / Next Documents
Previous: 2025-23865 — Determination of Regulatory Review Period for Purposes of Patent Extension; LEQEMBI
The FDA has officially set the review period for LEQEMBI, a new medicine, so its patent can be extended. This helps the company protect their invention longer, which might affect when generic versions can appear. If anyone thinks the dates are wrong or wants to challenge the company’s effort during review, they must act by early 2026.
Next: 2025-23868 — Determination of Regulatory Review Period for Purposes of Patent Extension; ZELSUVMI
The FDA has set the official review period for the drug ZELSUVMI, which helps the company extend its patent protection. This means the drug maker could get extra time to keep their invention exclusive, potentially affecting when generic versions can enter the market. People can comment or challenge these dates by early 2026, so stay tuned if you have info to share!